2024-520385-57-01RecruitingPhase 1
A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus
Climb Bio Inc.8 sites in 4 countries11 target enrollmentStarted: October 31, 2025Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 11
- Locations
- 8
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Janaki Subramanyam
Scientific
Climb Bio Inc.
Study Sites (8)
Loading locations...
Similar Trials
Recruiting
Phase 1
A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension.Chronic Kidney Disease2025-522336-14-00Bayer AG36
Completed
Not Applicable
茚达特罗格隆溴铵吸入粉雾剂（规格：110 μg/50 μg）生物等效性研究CTR2025313910
Recruiting
Phase 1
A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesityObesity2024-512332-29-00Boehringer Ingelheim International GmbH30
Recruiting
Phase 2
Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand DiseaseNCT07273721Medical University of Vienna6
Active, not recruiting
Not Applicable
布地奈德福莫特罗吸入粉雾剂（II）在健康人体的生物等效性预试验CTR2025491716